LDR — Investor Day (February 2016)
97 slides from LDR's investor day presentation, Feb 23, 2016
Slide 1: LDR Holding Corporation Analyst Day
LDR Holding Corporation Analyst Day February 23, 2016
Slide 2: Matt Norman, Director, Investor Relations
Matt Norman Director, Investor Relations 2
Slide 3: Forward Looking Statement & Disclaimer
Forward Looking Statement & Disclaimer 3 LDR cautions that statements in this presentation (including the oral commentary that accompanies it) are forward-looking statements. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our
Slide 4: Christophe Lavigne, President, Chief Executive Officer
Christophe Lavigne President, Chief Executive Officer 4
Slide 5: LDR At-A-Glance
Focus on Spine • Two Exclusive Technology Platforms VerteBRIDGE ® Mobi ® • Represented over 92% of Revenue in 2015 Attractive Financial Profile • $164M Revenue in 2015 • ~28% Exclusive Technology CAGR Since 2012 • 83.4% Gross Margin in 2015 Geographic Mix • U.S.: 81% Revenue in 2015 • OUS: 19% R
Slide 6: Experienced Management Team
Experienced Management Team 6 Christophe Lavigne Chairman, President and CEO • Founder • 23 years in spine André Potgieter EVP, U.S. Sales • 23 years in spine • LDR since 2007 Bob McNamara EVP, Chief Financial Officer • 23 years in medical device and technology • Extensive experience in public and p
Slide 7: LDRH: A Story of Excellence
LDRH: A Story of Excellence 7 CDR Excellence Mobi-C® A New Surgical Excellence MIVo™ Excellence in Innovation Product Pipeline Vision for the Future
Slide 8: LDRH: Reporting Structure
LDRH: Reporting Structure 8 Beginning in 2016, we will breakout revenue in the following three categories: Mobi-C • Breakout between Mobi-C U.S. and OUS • No breakout Mobi-C one and two-level VerteBRIDGE products, new MIVo products and Mobidisc • Global number • No breakout by product category • Ped
Slide 9: Mobi-C Cervical Disc Replacement Device
Mobi-C Cervical Disc Replacement Device • First and only artificial cervical disc approved in the U.S. for both one and two-level indication • U.S. Approval in August 2013 • PMAs started in 2005 • One of the largest prospective, randomized clinical studies ever completed in spine • ~600 patients: 24
Slide 10: Mobi-C: A Unique Design
Mobi-C: A Unique Design GLUPR a passion for innovation
Slide 11: Mobi-C: Market Status
Tailwinds • First 5-year peer reviewed publications available in Q1 2016 • Superiority claim for Mobi-C over fusion for two-level indication at 5 years (Q4 2015) • Cost efficiency study at 2 years (JAMA Surgery 2014) and at 5 years (JNS 2016 ) • NASS coverage policy recommendation for both one and t
Slide 12: The Last Years Have Established a Foundation for Long-Term Mobi-C Success
The Last 2 Years Have Established a Foundation for Long-Term Mobi-C Success 12 Reimbursement 179M* lives covered for one-level indication 35M* lives covered for two-level indication Cat. 1 CPT code in place for one and two-level DRG code in place NASS reimbursement recommendation Clinical Evidence A
Slide 13: In 2015, we sold more than $1M of Mobi-C per week
In 2015, on average, we sold more than 13 $1M of Mobi-C per week
Slide 14: Mobi-C Revenue History
14 $0 $10 $20 $30 $40 $50 $60 $70 2013 2014 2015 M ill ion s Mobi-C Revenue US OUS U.S. Mobi-C CAGR = 259% Total Mobi-C CAGR = 129% U.S. Mobi-C $51.7 $28.8 79.2% Total Mobi-C $61.2 $37.6 62.7% Mobi-C Revenue History
Slide 15: Mobi-C: Today
Mobi-C: Today 15 Global 2015 CDR Market ($150M to $200M) LDRH Estimates LDRH 30% - 40% Rest of Market 60% – 70% Establishing a Leadership Position in CDR Market within 2 years Post U.S. Launch In just 2 years, Mobi-C has captured 30% – 40% global market share, generating more than $61M revenue in 20
Slide 16: Mobi-C: The Market Potential
Market share shifting from existing $1.2B** U.S. cervical fusion market to CDR market Mobi-C: The Market Potential 16 Global CDR Market potential is estimated to be $800M+*, representing the fastest growing segment in the spine industry Dri ve rs Growing weight of clinical evidence in support of CDR
Slide 17: Mobi-C: Catalysts
Sales Coverage: Increase U.S. territory coverage with additional sales agencies and direct representation Training: Additional surgeons being trained on Mobi-C (~3,800 untrained today) Mobi-C: Catalysts 17 NASS Recommendation: In Q4 2015, NASS issued recommendation for reimbursement coverage for bot
Slide 18: Mobi-C: Long Term Vision
Mobi-C: Long Term Vision 18 Today: $1,000,000 per week Future Potential: $1,000,000 per day 100% territory coverage of the U.S. spine surgeon community Full reimbursement coverage for both one and two-level cervical disc replacement Cervical Disc Replacement accepted as the new standard of care for
Slide 19: MIVo Minimal Implant Volume Surgery
MIVo™ Minimal Implant Volume Surgery Introducing a new segment in the market place 19
Slide 20: MIVo: Minimal Implant Volume Unique Offering
MIVo: Minimal Implant Volume Unique Offering Creating a New Market Segment MIVo is a New Surgical Philosophy for treatment of the lumbar and cervical spine VerteBRIDGE Plating Technology as the Cornerstone of MIVo fusion No Pedicle Screws when used for lumbar spine The aim is to Reduce the Volume of
Slide 21: MIVo: Lumbar Fusion Products
ROI-A® Oblique 510(k) cleared • Cornerstone of MIVo is our VerteBRIDGE technology and the inherent stability of the interbody construct • 5 different approaches, 11 surgical alternatives: • Anterior, Anterior Oblique, Lateral, Postero lateral (New), and Posterior (New) • ROI-A, ROI-A Oblique, Avenue
Slide 22: LDRH: Pipeline
In the next 3 years, LDR will introduce 8 new exclusive products under MIVo, including Avenue T, InterBRIDGE, FacetBRIDGE, Avenue P, and others 7 new products will address the MIVo lumbar fusion market creating a new market opportunity New products will address the cervical market to complement our
Slide 23: Additive Manufacturing
Additive Manufacturing • Exclusive partnership with Poly-Shape, one of the most advanced companies in additive manufacturing in Europe (serving Formula One™ race teams and companies developing aerospace applications) • Minority investment in the company occurred in Q4 2015 (including a seat on the P
Slide 24: Vision for the Near Future
Be the cervical disc worldwide leader with Mobi-C Expand U.S. sales coverage via our hybrid distribution model and maximize revenue with broader product portfolio Worldwide representation with direct entities in key markets Vision for the Near Future Introduce a new surgical philosophy, MIVo, suppor
Slide 25: James Burrows, Executive Vice President, Chief Operating Officer
James Burrows Executive Vice President, Chief Operating Officer 25
Slide 26: Operations, Manufacturing, Engineering
Operations 26 Manufacturing Engineering
Slide 27: IP Portfolio
IP Portfolio Issued U.S. Patents 47 Pending U.S. Applications 35 Issued O.U.S. Patents 400+ Pending O.U.S. Applications 85+ Unique Product Portfolio Broad and Deep IP Coverage No Patent Litigation to Date on Exclusive Technologies As of 12/31/15 27
Slide 28: Global Offices and Facilities
Global Offices and Facilities • 67.4K sq-ft under lease • ~22K sq-ft being added in Q2 2016 to support company growth 28 • New facility is in final stages of construction • 10-year lease of approximately 83K sq-ft • Expected completion and move Q2 2016 • Additional R&D office located in Bordeaux Oth
Slide 29: LDR Supply Chain
LDR Supply Chain 29 LDR utilizes contract suppliers for all manufacturing processes • Key strategic supplier for each product line • Developing 2nd and 3rd suppliers for each product line • Majority of suppliers are located in France
Slide 30: LDR Development and Registration Process
LDR Development and Registration Process Product Development CE File Completion • During the Development Process, work begins on the CE registration and clinical plans • CE file completion allows for product introduction throughout the EU 30
Slide 31: LDR Development and Registration Process
LDR Development and Registration Process Product Development CE File Completion France & EU Beta-Launch U.S. 510K Clearance Process • Concurrent with our Beta-Launch in Europe we begin the 510(k) process in the U.S. • 510(k) process typically requires 30-180 days 31
Slide 32: LDR Development and Registration Process
LDR Development and Registration Process Product Development CE File Completion France & EU Beta-Launch U.S. 510K Clearance Process U.S. Beta-Launch France & EU Full Launch • Typically the U.S. Beta-Launch begins as we continue the EU Beta-Launch 32
Slide 33: LDR Development and Registration Process
LDR Development and Registration Process • U.S. Full Launch follows U.S. and EU Beta Launches as we begin our R.O.W. registration process • R.O.W. registrations are short for some countries but can take 2-3 years for others (Japan, China, Brazil) • LDR utilizes local consultants/agencies in some cou
Slide 34: LDR Development and Registration Process: Class III Device
LDR Development and Registration Process Product Development CE File Completion France & EU Beta-Launch U.S. 510K Clearance Process R.O.W. Registrations and Launches U.S. Beta-Launch U.S. Full Launch France & EU Full Launch Class III Device (Mobi-C) IDE and PMA Process • For Class III Products, like
Slide 35: Regulatory Portfolio
Regulatory Portfolio 35 ROI-C® Lordotic ROI-A® Oblique Avenue® L ROI-C® Easyspine® MC+® ROI-T® ROI® SpineTune® TL C-Plate® Mobidisc® Mobi-C® Mobi-C MIVo Traditional ROI-A® • LDR has been issued more than 200 product registrations, approvals, or clearances • Mobi-C and VerteBRIDGE products are regist
Slide 36: Mobi-C History and IDE/PMA Process
Mobi-C History and IDE/PMA Process 36 2005 2006 2008 2010 2011 2012 2013 2015 July 2005 – Pre-IDE Meeting with FDA October 2005 – Initial Submission to FDA for IDE Study March 2006 – IDE Approval April 2006 – First Patient Enrolled March 2008 – Last Patient Enrolled March 2010 – 2-Year Follow-up com
Slide 37: Comparison of One and Two-Level Overall Trial Success Through 5 Years
Comparison of One and Two-Level Overall Trial Success Through 5 Years 37 One-Level Overall Success Rates Two-Level Overall Success Rates 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 24M 36M 48M 60M P at ie n t P o p u la ti o n (% ) One-Level Mobi-C ACDF 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 24
Slide 38: Secondary Surgeries at Index Level Through Years
Secondary Surgeries at Index Level Through 5 Years 38 Mobi-C patients had fewer secondary surgeries than ACDF at all timepoints One-Level Secondary Surgeries Two-Level Secondary Surgeries 0% 2% 4% 6% 8% 10% 12% 14% 16% 18% 24M 36M 48M 60M % o f R an d omi ze d P at ie n ts One-Level Mobi-C ACDF 0% 2
Slide 39: Two-Level Adjacent Level Degeneration from Baseline Through 5 Years
Two-Level Adjacent Level Degeneration from Baseline Through 5 Years 39 Mobi-C patients demonstrated less adjacent level degeneration than ACDF at all timepoints Superior Adjacent Segment Inferior Adjacent Segment 0% 10% 20% 30% 40% 50% 60% 70% 80% 12M 24M 36M 48M 60M Two-Level Superior Adjacent Segm
Slide 40: Mobi-C Long-Term 5-Year Labeling
Strong and consistent 2-year and 5-year clinical data Obtained FDA approval in October 2015 to use our clinical evidence at 5 years, including Superiority at 5 Years This approval further supports our marketing of Mobi-C and may assist in obtaining reimbursement coverage Mobi-C Long-Term 5-Year Labe
Slide 41: Mobi-C Long-Term 7-Year Results: Follow-Up Rates
Mobi-C Long-Term 7-Year Results 41 Exceptional Mobi-C Patient Follow-Up Rates For One and Two-Level: More than 80% Closure of the Study 7-Year follow-up represents the end of the FDA requirement and initiates the closure of the study for Mobi-C
Slide 42: Mobi-C Long-Term 7-Year Results: Site Closures
Mobi-C Long-Term 7-Year Results 42 Site Closures LDR plans to close out all sites by the end of 2016 Quality of the Results 7-year results consistent with findings at 5 years and we believe that we will statistically maintain: • Non-inferiority for one-level • Superiority for two-level
Slide 43: Clinical Presentations & Abstracts
Clinical Presentations & Abstracts Presentations in 2015 • 46 Presentations (posters and podium) were given in 2015 on LDR products • 36 Podium presentations were given on Mobi-C results at 15 international meetings Upcoming for 2016 • 7 Presentations accepted for ISASS April 2016 • 5 Podium & 1 Pos
Slide 44: Mobi-C Published Literature
Mobi-C Published Literature Growing Weight of Clinical Evidence Supporting Mobi-C Published: • Davis, et al; J Neurosurg Spine, Jan. 2015; Two- level results at 48 months • Hisey, et al; J Spinal Disord Tech, May. 2015; One-level results at 48 months • Bae, et al; Spine, June. 2015; One and Two-Leve
Slide 45: Joe Ross, Executive Vice President, Global Marketing
Joe Ross Executive Vice President, Global Marketing 45
Slide 46: Agenda
V. Evolution of Sales Channel VI. Update on Direct Sales Initiative Agenda 46 I. U.S. Marketing Organization II. Mobi-C® Cervical Disc III. U.S. Reimbursement IV. MIVo™ Fusion Marketing Sales
Slide 47: Global Marketing Organization
Market Development Professional Medical Education Communications & Events Healthcare Policy & Reimbursement Global Marketing Organization 47
Slide 48: The Mobi-C Opportunity
© passion for innovation The Mobi-C Opportunity
Slide 49: Cervical Disc Replacement Current U.S. Market
Cervical Disc Replacement Current U.S. Market 49 A View of the Current U.S. Cervical Disc Market • Market estimates vary widely with reports estimating the U.S. cTDR market at <$100 - $200 million • A sample view in 2015: U.S. Cervical Disc Market $125,000,000* Industry Adjusted APP $7,000* Procedur
Slide 50: U.S. Cervical Disc Replacement Market Opportunity
U.S. Cervical Disc Replacement Market Opportunity Disc Replacement Indications 50 Market reports estimate approximately 300,000 anterior cervical procedures annually in the U.S. • Procedures of three levels or more are off-label for cervical disc replacement, leaving approximately 234,000 one and tw
Slide 51: U.S. Cervical Disc Replacement Market Opportunity
40% 60% 93,800 Procedures 140,700 Procedures U.S. Cervical Disc Replacement Market Opportunity 51 30% 70% 70,350 Procedures 164,150 Procedures Uses an industry adjusted APP of $7,000 50% 50% 117,250 Procedures 117,250 Procedures Mobi-C is uniquely well-positioned to be the market leader: • The first
Slide 52: First Mover Advantage in Two-Level CDR
First Mover Advantage in Two-Level CDR 2008 Globus Secure-C NuVasive PCM 2010 2009 2011 Medtronic Bryan 2007 2013 2012 One-Level Two-Level Off-Label Use Synthes Prodisc-C Medtronic Prestige ST Overall Clinical Superiority Claim Creates a Major Barrier to New Entrants LDR Mobi-C LDR Mobi-C Approval 2
Slide 53: Medical Education
Medical Education Cervical Solutions Training 2015 (Mobi-C and ROI-C) • Investment in training continued in 2015 • Numerous national and regional labs • Now more than 2,200 Surgeons Trained on Mobi-C 53 6,000 U.S. Spine Surgeons Mobi-C Trained 2,200 Not Trained 3,800
Slide 54: Mobi-C U.S. Surgeon Base Continuous Growth Since Launch
Mobi-C U.S. Surgeon Base Continuous Growth Since Launch 54 Q3:13 Q4:13 Q1:14 Q2:14 Q3:14 Q4:14 Q1:15 Q2:15 Q3:15 Q4:15 Number of S u rg eon s Mobi-C Individual Users Per Quarter
Slide 55: Mobi-C Reimbursement
© passion for innovation Mobi-C Reimbursement
Slide 56: Successful Reimbursement Strategy Has Three Related Components
Successful Reimbursement Strategy Has Three Related Components Coverage Payment Coding 56
Slide 57: Coding & Payment
Coding & Payment MS-DRG 2016 Medicare National Average Reimbursement 518 $17,270* * Represents a 65% increase from the DRG payment rate in 2014 CPT Code 2016 Medicare National Average Surgeon Reimbursement (inpatient and hospital outpatient) 22856 (one-level) $1,690 +22858 (two-level) $530 (incremen
Slide 58: Coverage: Mobi-C Recent Milestones
Coverage: Mobi-C Recent Milestones Five-Year FDA Claims • Via a comprehensive submission of our complete 5-year data set, we have recently received approval to use our clinical evidence at 5 years in our marketing and promotional materials; Including, superiority at 5 years for the two-level applica
Slide 59: Coverage: Mobi-C Recent Milestones
Coverage: Mobi-C Recent Milestones Medicare • Medicare silent on coverage for cervical arthroplasty nationally • Previously two contractors had cervical arthroplasty on non-covered services list (Noridian in West and First Coast in Florida) – Recently LDRH was able to get them to remove, so now no n
Slide 60: Coverage: Mobi-C Recent Milestones
Coverage: Mobi-C Recent Milestones Publications • Jackson et al. five-year, one-level and two-level secondary surgery outcomes e-published week of January 18, 2016 • Sent to all payers for review – key outcome for insurers • Ament et al. five-year, two-level cost-effectiveness study published week o
Slide 61: One-Level and Two-Level Coverage
One-Level and Two-Level Coverage • Univera Healthcare (Feb 2016) • Excellus BCBS (Feb 2016) • Capital BC (Dec 2015) • BCBS Massachusetts (Dec 2015) • BCBS NE Pennsylvania (Dec 2015) • BCBS North Carolina (Dec 2015) • Medi-Cal (Dec 2015) • BCBS Federal Employee Program (Nov 2015) • BCBS Nebraska (Oct
Slide 62: 2016 Reimbursement Strategy
2016 Reimbursement Strategy Communicate latest available evidence to national and regional payers in support of broad two-level coverage Build on the 2015 momentum Provide field reimbursement support to customers, educate and train new accounts, and develop key opinion leaders to work with payers Ut
Slide 63: MIVo Lumbar Fusion Surgery
MIVo Lumbar Fusion Surgery 63
Slide 64: MIVo Lumbar Fusion Market Opportunity
MIVo Lumbar Fusion Market Opportunity Source: iDATA 2015 U.S. Markets for Spinal Implants and US Markets for MIS MIVo Lumbar Fusion taps into one of the largest segments in spine, the multi-billion dollar Thoracolumbar Fusion Market $- $500 $1,000 $1,500 $2,000 $2,500 $3,000 $3,500 $4,000 2016 Thora
Slide 65: MIVo Lumbar Fusion Surgery
MIVo Lumbar Fusion Surgery Traditional (Open) • Large exposure, significant tissue disruption • Large implant volume • 1 large incision 65 Minimally Invasive (MIS) • Small exposure, reduced tissue disruption • Large implant volume • 4 small incisions Minimal Implant Volume (MIVo) • Small exposure, m
Slide 66: MIVo Lumbar Fusion Surgery
MIVo Lumbar Fusion Surgery MIS Lumbar Spine Fusion MIVo Lumbar Spine Fusion Anterior Interbody cages - L4-5, L5-S1 Posterior MIS pedicle screws - L4, L5, S1 Anterior Interbody cages - Avenue L L4-L5 - ROI-A L5-S1 Posterior Interspinous fixation - L4-L5 only 66
Slide 67: MIVo Lumbar Fusion Surgery
MIVo Lumbar Fusion Surgery 67
Slide 68: MIVo Mechanical Testing
100% 39% 7% 7% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Intact Disc Flexion-Extension Ra n ge of Mot io n C om b in e R O M as % o f In ta ct Intact Disc MIVo Lumbar Stand-Alone (ROI-A Cage + VerteBRIDGE Plates) MIVo Lumbar 360 (ROI-A Cage + VerteBRIDGE Plates + InterBRIDGE) Traditional (ROI-A Ca
Slide 69: ALIF ROI-A ALIF Cage
ALIF ROI-A® ALIF Cage Anterior (0°) MIVo Lumbar Fusion Surgery 69
Slide 70: Oblique ALIF ROI-A Oblique ALIF Cage
Oblique ALIF ROI-A® Oblique ALIF Cage Oblique (25°) MIVo Lumbar Fusion Surgery 70
Slide 71: LLIF Avenue L Lateral Lumbar Cage
LLIF Avenue® L Lateral Lumbar Cage Lateral (90°) MIVo Lumbar Fusion Surgery 71
Slide 72: TLIF Avenue T TLIF Cage
TLIF Avenue® T TLIF Cage Transforaminal (135°) MIVo Lumbar Fusion Surgery 72
Slide 73: PLIF Avenue P PLIF Cages
PLIF Avenue® P PLIF Cages Posterior (180°) MIVo Lumbar Fusion Surgery 73
Slide 74: MIVo Lumbar Fusion Surgery
ALIF Oblique ALIF LLIF MIVo Lumbar Fusion Surgery TLIF PLIF 74
Slide 75: A New Philosophy: MIVo Lumbar Fusion Surgery
Extending the benefits of VerteBRIDGE to new applications in the lumbar spine • Minimally Invasive • 45% – 60% reduction of spinal hardware volume • Reduced surgical trauma • No pedicle screws, preserving them for future interventions • Extending the benefits of MIVo to the next surgery if needed A
Slide 76: U.S. Sales
© passion for innovation® U.S. Sales
Slide 77: U.S. Sales Organization
U.S. Sales Organization Direct Representatives Independent Sales Agencies Regional Sales Manager (RSM) Direct Representatives Independent Sales Agencies Regional Sales Manager (RSM) 77
Slide 78: U.S. Sales 2016 Strategies
U.S. Sales 2016 Strategies 78 Continue to drive U.S. growth with Mobi-C Drive ROI-C growth thru Mobi-C cross-selling initiatives Introduce U.S. sales team to new MIVo lumbar products (FacetBRIDGE and InterBRIDGE) Increase U.S. sales channels, both Sales Agencies and Direct Representatives Increase s
Slide 79: Bob McNamara, Executive Vice President, Chief Financial Officer
Bob McNamara Executive Vice President, Chief Financial Officer 79
Slide 80: Revenue Growth Through Exclusive Technology
120 100 80 60 40 140 20 0 180 160 2014 $141.3M 88.5% 11.5% $90.9M 80.1% 19.9% 2013 $111.6M 82.9% 17.1% 2012 2015 $164.5M 92.7% 7.3% Revenue Growth Through Exclusive Technology 80 22% CAGR – Total Revenue 28% CAGR – Exclusive Revenue 16% 2015 Growth v 2014 (21% CC) Exclusive Traditional $152.4M $125.
Slide 81: Global Base of Revenue
Global Base of Revenue 81 • LDR was founded in France • Leverage international surgeon input into new innovations and more easily extend international presence • Direct end-user pricing and sales channel control • Broad global presence – 19% of revenue outside the U.S. LDR’s Global Background Year E
Slide 82: Strong Gross Margins
Strong Gross Margins 82 83.8% 83.9% 82.7% 83.4% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 2012 2013 2014 2015 Exclusive Technology Supply Agreements Geographic Revenue Presence
Slide 83: Financial Performance
Financial Performance 83 *Adjusted for stock-based compensation expense Revenue $90.9 $111.6 $141.3 $164.5 Growth % 16.6% 22.7% 26.6% 16.4% Gross Profit $76.1 $93.6 $116.8 $137.2 Gross Margin % 83.8% 83.9% 82.7% 83.4% Operating Income (Loss) ($1.3) ($2.3) ($10.7) ($22.5) Net Income (Loss) ($9.7) ($2
Slide 84: Revenue Growth by Category 2015 Using Prior Reporting Structure
Revenue Growth by Category 2015 Using Prior Reporting Structure 84 *Revenue on a constant currency basis is calculated using the average foreign exchange rates in the monthly periods during the previous year and applying these rates to foreign-denominated revenue in the corresponding monthly periods
Slide 85: Revenue Growth by Category 2015 Using New Reporting Structure
Revenue Growth by Category 2015 Using New Reporting Structure 85 U.S. Mobi-C Revenue in 2015 was $51.7M (up 79.2% over 2014) Total Revenue $44.5 12.7% 16.2% $164.5 16.4% 21.3% U.S. $36.9 15.4% 15.4% $133.8 22.1% 22.1% O.U.S. $7.6 1.0% 19.4% $30.6 (3.3%) 18.5% Mobi-C $18.3 54.3% 57.6% $61.2 62.7% 68.
Slide 86: Balance Sheet
Balance Sheet 86 Cash and Cash Equivalents $56.7 $73.9 $115.1 Working Capital $55.4 $98.9 $148.0 Total Assets $128.0 $161.8 $226.6 Short Term Debt, Net of Disc. $22.6 $5.4 $5.1 Long Term Debt, Net of Disc. $2.8 $19.6 $0.7
Slide 87: 2016 Guidance
2016 Guidance Revenue 2015: $164.5M • Guidance for Revenue in 2016: $187.5M to $189.5M • Revenue Growth Rate for 2016: 14.0% to 15.2% • Potential Foreign Exchange Impact: Up to 1.0% • Constant Currency (CC) Revenue in 2016: $189.1M to $191.1M • CC Revenue Growth Rate for 2016: 15.0% to 16.2% Flow of
Slide 88: Creating Sustainable Value For Shareholders
Creating Sustainable Value For Shareholders 88 Value Creation Execution Strategic Drivers Clinical Evidence – Growing library of clinical publications Reimbursement Upside – Implemented effective reimbursement strategy Expanding Sales Channels – Built direct sales force (68 reps) and added sales age
Slide 89: Christophe Lavigne, President, Chief Executive Officer
Christophe Lavigne President, Chief Executive Officer 89
Slide 90: Vision for the Near Future
Be the cervical disc worldwide leader with Mobi-C Expand U.S. sales coverage via our hybrid distribution model and maximize revenue with broader product portfolio Worldwide representation with direct entities in key markets Vision for the Near Future Introduce a new surgical philosophy, MIVo, suppor
Slide 91: Thank You
Thank You 91
Slide 92: Appendix: Non-GAAP Recons
© passion for innovation Appendix Non-GAAP Recons
Slide 93: Reconciliation of Net Loss to Non-GAAP Financial Measures
RECONCILIATION OF NET LOSS TO NON-GAAP FINANCIAL MEASURES 93 Net loss ($9.7) ($27.9) ($11.0) ($15.9) Interest (income) expense, net 4.6 10.1 0.9 0.5 Income tax (benefit) expense 1.2 1.7 1.4 (6.1) Depreciation and amortization 3.1 4.0 4.7 6.3 EBITDA (0.8) (12.1) (4.0) (15.2) Stock-based compensation
Slide 94: Reconciliation of GAAP Revenue to Non-GAAP Revenue on a Constant Currency Basis
RECONCILIATION OF GAAP REVENUE TO NON-GAAP REVENUE ON A CONSTANT CURRENCY BASIS 94 Total Revenue $44.5 $1.4 $45.9 $39.5 $6.4 16.2% U.S. $36.9 — $36.9 $32.0 $4.9 15.4% O.U.S. $7.6 $1.4 $9.0 $7.5 $1.5 19.4% Exclusive $41.6 $0.9 $42.4 $35.8 $6.6 18.3% Cervical $32.1 $0.7 $32.8 $25.5 $7.3 28.6% Lumbar $
Slide 95: Reconciliation of GAAP Revenue to Non-GAAP Revenue on a Constant Currency Basis
RECONCILIATION OF GAAP REVENUE TO NON-GAAP REVENUE ON A CONSTANT CURRENCY BASIS 95 Total Revenue $164.5 $6.9 $171.4 $141.3 $30.1 21.3% U.S. $133.8 — $133.8 $109.6 $24.2 22.1% O.U.S. $30.6 $6.9 $37.5 $31.7 $5.9 18.5% Exclusive $152.4 $4.4 $156.8 $125.0 $31.8 25.4% Cervical $114.8 $3.5 $118.3 $87.0 $3
Slide 96: Reconciliation of GAAP Revenue to Non-GAAP Revenue on a Constant Currency Basis
RECONCILIATION OF GAAP REVENUE TO NON-GAAP REVENUE ON A CONSTANT CURRENCY BASIS 96 Total Revenue $44.5 $1.4 $45.9 $39.5 $6.4 16.2% U.S. $36.9 — $36.9 $32.0 $4.9 15.4% O.U.S. $7.6 $1.4 $9.0 $7.5 $1.5 19.4% Mobi-C $18.3 $0.4 $18.7 $11.9 $6.8 57.6% MIVo $23.3 $0.5 $23.7 $24.0 ($0.3) (1.1%) Traditional
Slide 97: Reconciliation of GAAP Revenue to Non-GAAP Revenue on a Constant Currency Basis
RECONCILIATION OF GAAP REVENUE TO NON-GAAP REVENUE ON A CONSTANT CURRENCY BASIS 97 Total Revenue $164.5 $6.9 $171.4 $141.3 $30.1 21.3% U.S. $133.8 — $133.8 $109.6 $24.2 22.1% O.U.S. $30.6 $6.9 $37.5 $31.7 $5.9 18.5% Mobi-C $61.2 $2.1 $63.3 $37.6 $25.7 68.3% MIVo $91.3 $2.3 $93.5 $87.4 $6.1 7.0% Trad